-
2023-505261-84-00
5
2020-10-06
Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-523641-10-00
3
2026-05-18
Healthy / hepatic impaired volunteers only study to assess PK paramete
-
2025-521647-20-00
3
2026-05-12
hepatic impairment
-
2025-523975-48-00
5
2026-05-08
Obesity
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-523974-18-00
5
2026-04-30
Obesity
-
2025-523260-20-00
4
2026-04-28
type 2 diabetes
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-523658-15-00
5
2026-04-10
Obesity
-
2025-522231-34-00
5
2026-03-31
Diabetic Macular Edema
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2025-522347-18-00
4
2025-11-26
Major Depressive Disorder (MDD), with or without Anxious Distress
-
2025-521947-19-00
3
2025-11-19
Healthy, Hepatic Insufficiency
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig